Pharma BD Deal Intelligence
Bloomberg framed the acquisition as Zoetis pivoting into one of animal health's highest-growth segments, leveraging PHARMAQ's category leadership in Norwegian…
Fierce Pharma reported Zoetis shareholders 'applauded' the $765M PHARMAQ deal — shares rose >5% the day of announcement on the combination of strong…
TheStreet flagged the deal as accretive long-term but neutral to 2016 adjusted earnings, with aquaculture serving as a secular protein-demand growth thesis…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Zoetis agreed to acquire Norway-based PHARMAQ, the global leader in aquaculture health, from Permira-led investors for approximately $765M, expanding Zoetis into fish health and vaccines. Borderline by pharma vs. animal health classification — included as platform-level vaccine deal.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Zoetis Inc. / PHARMAQ Holding AS (this deal) | 2015 | $765M | 82 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
| Pamplona Capital Management, LLP / PAREXEL International Corporation | 2017 | $5.0B | 90 |
← Browse all deals · How we score deals
More: 2015 deals · Other deals